Related Experiment Video
Updated: Jan 1, 2026

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome
Published on: June 15, 2016
STAT3 Activation and Oncogenesis in Lymphoma
Fen Zhu1,2, Kevin Boyang Wang3, Lixin Rui1,2
1Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA.
Abstract:
Signal transducer and activator of transcription 3 (STAT3) is an important and the most studied transcription factor in the Janus kinase (JAK)/STAT signaling pathway. STAT3 mediates the expression of various genes that play a critical role in many cellular and biological processes, such as cell proliferation, survival, differentiation, migration, angiogenesis, and inflammation. STAT3 and associated JAKs are activated and tightly regulated by a variety of cytokines and growth factors and their receptors in normal immune responses. However, abnormal expression of STAT3 leads to its constitutive activation, which promotes malignant transformation and tumor progression through oncogenic gene expression in numerous human cancers. Human lymphoma is a heterogeneous malignancy of T and B lymphocytes. Constitutive signaling by STAT3 is an oncogenic driver in several types of B-cell lymphoma and most of T-cell lymphomas. Aberrant STAT3 activation can also induce inappropriate expression of genes involved in tumor immune evasion such as PD-L1. In this review, we focus on the oncogenic role of STAT3 in human lymphoma and highlight potential therapeutic intervention by targeting JAK/STAT3 signaling.
Insights
Constitutive activation of Signal transducer and activator of transcription 3 (STAT3) drives human lymphoma progression. Targeting the Janus kinase (JAK)/STAT3 pathway offers a promising therapeutic strategy for these cancers.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Signal transducer and activator of transcription 3 (STAT3) is a key transcription factor in the Janus kinase (JAK)/STAT pathway.
- STAT3 regulates critical cellular processes including proliferation, survival, and inflammation.
- Aberrant STAT3 activation is implicated in numerous human cancers, including lymphoma.
Purpose of the Study:
- To review the oncogenic role of STAT3 in human lymphoma.
- To highlight therapeutic strategies targeting the JAK/STAT3 signaling pathway in lymphoma.
Main Methods:
- Literature review focusing on the role of STAT3 in lymphoma pathogenesis.
- Analysis of studies investigating JAK/STAT3 signaling in various lymphoma subtypes.
- Examination of therapeutic interventions targeting the JAK/STAT3 pathway.
Main Results:
- Constitutive STAT3 signaling acts as an oncogenic driver in both B-cell and T-cell lymphomas.
- Aberrant STAT3 activation contributes to tumor immune evasion by upregulating genes like PD-L1.
- Targeting JAK/STAT3 signaling demonstrates potential for lymphoma treatment.
Conclusions:
- STAT3 plays a critical oncogenic role in human lymphoma.
- Inhibition of the JAK/STAT3 pathway represents a viable therapeutic approach for lymphoma patients.
Related Concept Videos
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The JAK-STAT Signaling Pathway
The Intrinsic Apoptotic Pathway
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...

